Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Mevalonic Aciduria, Mevalonate Kinase Deficiency, Immune System Diseases, Periodic Fever Syndromes, Hereditary, Lipid Metabolism, Inborn Errors
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions: The Complete Health Improvement Program; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 389 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Familial Hypercholesterolemia
Interventions: Dietary intervention; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity
Interventions: Flexible Sigmoidoscopy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Ezetimibe, Phytosterols + ezetimibe, Placebo; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions: AlmegaPL (FDA NDIN # 826); Dietary Supplement
Lead sponsor: Qualitas Health; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Houston, Texas

Conditions: Dyslipidemia
Interventions: Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 57
States / cities: Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more

Conditions: Intermittent Fasting
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 21 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 65
States / cities: Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more

Conditions: Hypercholesterolemia
Interventions: ezetimibe, placebo; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Lysosomal Acid Lipase Deficiency
Interventions: Sebelipase Alfa, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more

Conditions: Serum Cholesterol, Gut Microbiome
Interventions: Milk Polar Lipids, Milk Fat; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Pre-Diabetes
Interventions: Functional Ingredient Group, Control Ingredient Group; Dietary Supplement
Lead sponsor: University of Manitoba; Other
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers, Hypercholesterolemia
Interventions: LY3015014, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Elevated HMB Excretion
Interventions: Statin user; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 65 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Ischemic Stroke
Interventions: Endovascular thrombectomy with any FDA-approved category POL or NRY device, Medical Management; Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 41
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 34 more

Conditions: Coronary Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: 3H-Cholesterol; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: LY3015014, Placebo, Statin, Ezetimibe; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Encino, California • Lancaster, California • Spring Valley, California + 12 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, PF-04950615 (RN316); Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more

Conditions: Endometriosis
Interventions: Atorvastatin; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
Interventions: LY3561774, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Waterbury, Connecticut • Oxon Hill, Maryland • Fall River, Massachusetts + 3 more

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions: The Complete Health Improvement Program; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: Not listed
Enrollment: 512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Obsessive-Compulsive Disorder
Interventions: Psilocybin (0.25mg/kg), Niacin (250mg); Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project

Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia

Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells

Phytosterols, Ezetimibe, and Cholesterol Metabolism

AlmegaPL CV Health Open Label Study

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

Evaluation of Dietary Milk Polar Lipids on Serum Cholesterol and Gut Microbiota in Healthy Adults

Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes

A Study of LY3015014 in Healthy Participants With High Cholesterol

Cholesterol and Statin in Healthy Adults

StrokeNet Thrombectomy Endovascular Platform

Atherosclerosis in the Coronary and Carotid Arteries

Reverse Cholesterol Transport (RCT) Study

A Study of LY3015014 in Participants With High Cholesterol

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

A Study of LY3561774 in Participants With Mixed Dyslipidemia

Retrospective Evaluation of Athens Complete Health Improvement Program (CHIP) Database

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.